These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26162296)

  • 1. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
    Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
    J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
    APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
    Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
    Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
    Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
    Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent.
    Mbeutcha A; Lucca I; Margulis V; Karam JA; Wood CG; de Martino M; Mathieu R; Haitel A; Xylinas E; Kluth L; Rouprêt M; Karakiewicz PI; Briganti A; Rink M; Rieken M; Weizer AZ; Raman JD; Rioux-Leclecq N; Bolenz C; Bensalah K; Lotan Y; Seitz C; Remzi M; Shariat SF; Klatte T
    World J Urol; 2016 Aug; 34(8):1155-61. PubMed ID: 26658888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after urothelial recurrence in bladder cancer patients undergoing radical cystectomy.
    Mitra AP; Alemozaffar M; Harris BN; Schuckman AK; Skinner EC; Daneshmand S
    Urology; 2014 Dec; 84(6):1420-6. PubMed ID: 25306479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.
    Hoffmann AC; Wild P; Leicht C; Bertz S; Danenberg KD; Danenberg PV; Stöhr R; Stöckle M; Lehmann J; Schuler M; Hartmann A
    Neoplasia; 2010 Aug; 12(8):628-36. PubMed ID: 20689757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma.
    Kim SP; Frank I; Cheville JC; Thompson RH; Weight CJ; Thapa P; Boorjian SA
    J Urol; 2012 Aug; 188(2):405-9. PubMed ID: 22704101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.
    Ceppi P; Longo M; Volante M; Novello S; Cappia S; Bacillo E; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
    J Thorac Oncol; 2008 Jun; 3(6):583-9. PubMed ID: 18520795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer.
    Laurberg JR; Brems-Eskildsen AS; Nordentoft I; Fristrup N; Schepeler T; Ulhøi BP; Agerbaek M; Hartmann A; Bertz S; Wittlinger M; Fietkau R; Rödel C; Borre M; Jensen JB; Orntoft T; Dyrskjøt L
    BJU Int; 2012 Dec; 110(11 Pt C):E1228-36. PubMed ID: 23046361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy.
    Sun JM; Sung JY; Park SH; Kwon GY; Jeong BC; Seo SI; Jeon SS; Lee HM; Jo J; Choi HY; Lim HY
    BMC Cancer; 2012 May; 12():187. PubMed ID: 22616552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
    Chang IW; Lin VC; Hung CH; Wang HP; Lin YY; Wu WJ; Huang CN; Li CC; Li WM; Wu JY; Li CF
    World J Urol; 2015 Nov; 33(11):1777-89. PubMed ID: 25813210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
    May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
    Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
    Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP
    J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.